Failure to Follow Procedure: Bombay High Court Scraps ‘Lame’ Drug Prosecution

In a significant ruling for the pharmaceutical industry, the Bombay High Court has quashed a criminal case initiated against C.B. Healthcare, emphasizing that regulatory authorities cannot disregard mandatory procedural timelines. Presiding over the case, Justice N.J. Jamadar deemed the prosecution "lame," criticizing the authorities for a series of procedural lapses that effectively stripped the manufacturer of its right to a fair defense.

A Timeline of Regulatory Delay

The dispute centers on a batch of Fexinol-12 tablets, manufactured by C.B. Healthcare. In November 2016, a Drugs Inspector collected samples from a medical store in Silvassa. While the samples were sent to the Central Drugs Testing Laboratory, the report declaring the medicine "not of standard quality" was only issued in July 2017—well beyond the 60-day window mandated by Rule 45 of the Drugs Rules, 1945. The prosecution was not initiated until September 2021, nearly five years after the initial inspection.

The petitioners, including the firm and its partners, moved the High Court, asserting that the long delay, combined with the failure to provide the manufacturer with a sample portion, rendered any meaningful defense impossible.

Legal Contentions

The petitioners raised several grounds for relief, primarily pointing to: * Procedural Violation: Breach of Rule 45 regarding the mandatory timeframe for sample testing. * Denial of Essential Rights: Violation of Section 23(4) of the Drugs & Cosmetics Act by failing to provide one portion of the sample to the manufacturer, thereby preventing them from seeking independent retesting. * Vicarious Liability: Lack of specific averments illustrating how the individual partners were responsible for the day-to-day business of the firm.

The respondent, the Union of India, defended the timeline by citing technical challenges, such as the unavailability of reference standards, which they claimed necessitated the delay.

The Court’s Analysis: A ‘Lame Prosecution’

Justice Jamadar rejected the state's justifications. The Court held that Rule 45 is "peremptory" and any extension for testing requires formal approval, which was not sought in this instance. More importantly, the Court underscored that the right to retest a sample is a "valuable right" granted to the accused. By the time the complaint was filed, the drug’s shelf life had expired, making it impossible to perform an accurate re-analysis.

Citing the Supreme Court’s decision in Laborate Pharmaceuticals India Ltd. v. State of Tamil Nadu , the Court noted that when a sample is not provided to the manufacturer, the manufacturer is deprived of its legal remedy to contest the analyst's findings, rendering the prosecution inherently unfair.

Key Observations

The High Court’s ruling included several pointed observations regarding the conduct of the prosecution:

> “The object behind prescribing the time limit for the testing and furnishing the report of analysis is not far to seek. Delay beyond the specified period has the propensity to render the report of analysis suspect as the properties of the drugs may be lost due to the lapse of time.”

> “Cumulatively, an invaluable right of the Petitioner No.1 to have the sample retested was defeated by a series of failures and inactions on the part of the Respondent.”

> “In the said case also, one part of the sample was not sent to the Appellant – Manufacturer and, instead, what was sent was only the report of the Government Analyst. In the backdrop of such facts, the Supreme Court enunciated that, when the part of the sample was not sent to the manufacturer, the manufacturer could not have got the same analysed.”

Final Decision and Implications

The High Court ordered the quashing of the criminal complaint in Special Case No.32 of 2021 . By ruling in favor of the petitioner, the Court has reinforced the principle that the state must adhere strictly to statutory procedures when initiating penal action. This decision serves as a powerful reminder to regulatory bodies that "process over substance" is not a mere technicality; it is a fundamental safeguard against the abuse of judicial processes, particularly when the passage of time can turn a legitimate investigation into a "lame" one.